Integra LifeSciences Holdings Corporation (IART)
| Market Cap | 5.71B |
| Revenue (ttm) | 1.53B |
| Net Income (ttm) | 216.44M |
| Shares Out | 84.70M |
| EPS (ttm) | 2.54 |
| PE Ratio | 26.55 |
| Forward PE | 18.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 406,591 |
| Open | 67.99 |
| Previous Close | 68.79 |
| Day's Range | 67.04 - 68.30 |
| 52-Week Range | 61.85 - 77.40 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 77.82 (+15.4%) |
| Earnings Date | Nov 2, 2021 |
About IART
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial...
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is 77.82, which is an increase of 15.39% from the latest price.
News
Integra (IART) Announces Preliminary Q4 & '21 Sales Results
Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.
Integra LifeSciences Reports Interim Q4 Sales Marginally Ahead Of Expectations
Integra LifeSciences Holdings Corp (NASDAQ: IART) expects Q4 FY21 sales of $404 million - $406 million, representing an increase of approximately 4% Y/Y on a reported basis and 8% on an organic basis. I...
5 Stocks To Watch For January 12, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects Shaw Communications Inc. (NYSE: SJR) to report quarterly earnings at $0.29 per share on revenue of $1.10 billion before the...
Integra LifeSciences Reports Preliminary Fourth Quarter and Full-Year 2021 Revenue and Plans $125 Million Share Repur...
PRINCETON, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fo...
Here's Why You Should Hold on to Integra (IART) Stock for Now
Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.
Integra (IART) Businesses Rebound Despite Supply Issues
Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.
Integra (IART) Down 13.2% Since Last Earnings Report: Can It Rebound?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up
Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.
Integra LifeSciences Stock Rises On Street-Beating Q3 Earnings, Raises FY21 EPS Guidance
Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares got a boost as Q3 adjusted EPS of $0.86 topped the consensus forecast of $0.72. Revenues increased 4.5% Y/Y (6.7% organically) to $386.9 m...
Integra LifeSciences (IART) Q3 Earnings and Revenues Top Estimates
Integra (IART) delivered earnings and revenue surprises of 19.44% and 0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences Reports Third Quarter 2021 Financial Results
Third Quarter 2021 Highlights
Integra LifeSciences Announces Jan De Witte as President and Chief Executive Officer
30-year healthcare and technology veteran with extensive global executive experience and diverse expertise in R&D, commercialization, product management, digital innovation and operations 30-year health...
Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra LifeSciences to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
PRINCETON, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2021 financial result...
Integra LifeSciences Announces Participation in Upcoming Investor Conferences
PRINCETON, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the...
Integra (IART) Up 1.5% Since Last Earnings Report: Can It Continue?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain Integra (IART) Stock for Now
Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).
Integra LifeSciences (IART) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up
Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.
Integra's Update On FY21 Acell Revenues To Weigh On Stock, Piper Sandler Says
Piper Sandler has raised the price target on Integra LifeSciences Holding Corporation (NASDAQ:IART) to $72 from $70 and reiterated a Neutral rating following the Q2 beat. The company posted Q2 EPS of $...
Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of 17.91% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Integra Lifesciences Q2 Earnings
Shares of Integra Lifesciences (NASDAQ:IART) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 139.39% over the past year to $0.79, which beat the esti...
Integra LifeSciences Reports Second Quarter 2021 Financial Results
Raises Full-Year 2021 Guidance Raises Full-Year 2021 Guidance
Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) Releases Favorable PriMatrix Clinical Outcome
Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.